- Home
- RDHL vs MBIO Comparison
RDHL vs MBIO Comparison
Compare RDHL & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDHL
- MBIO
- Stock Information
- Founded
- RDHL 2009
- MBIO 2015
- Country
- RDHL Israel
- MBIO United States
- Employees
- RDHL N/A
- MBIO N/A
- Industry
- RDHL Biotechnology: Pharmaceutical Preparations
- MBIO Biotechnology: Pharmaceutical Preparations
- Sector
- RDHL Health Care
- MBIO Health Care
- Exchange
- RDHL Nasdaq
- MBIO Nasdaq
- Market Cap
- RDHL 3.9M
- MBIO 4.7M
- IPO Year
- RDHL N/A
- MBIO N/A
- Fundamental
- Price
- RDHL $1.34
- MBIO $1.65
- Analyst Decision
- RDHL
- MBIO
- Analyst Count
- RDHL 0
- MBIO 0
- Target Price
- RDHL N/A
- MBIO N/A
- AVG Volume (30 Days)
- RDHL 142.3K
- MBIO 178.7K
- Earning Date
- RDHL 09-02-2025
- MBIO 08-08-2025
- Dividend Yield
- RDHL N/A
- MBIO N/A
- EPS Growth
- RDHL N/A
- MBIO N/A
- EPS
- RDHL N/A
- MBIO N/A
- Revenue
- RDHL $8,042,999.00
- MBIO N/A
- Revenue This Year
- RDHL $381.91
- MBIO N/A
- Revenue Next Year
- RDHL N/A
- MBIO N/A
- P/E Ratio
- RDHL N/A
- MBIO N/A
- Revenue Growth
- RDHL 23.17
- MBIO N/A
- 52 Week Low
- RDHL $1.06
- MBIO $0.89
- 52 Week High
- RDHL $12.50
- MBIO $21.95
- Technical
- Relative Strength Index (RSI)
- RDHL 42.30
- MBIO 46.95
- Support Level
- RDHL $1.31
- MBIO $1.56
- Resistance Level
- RDHL $1.48
- MBIO $1.88
- Average True Range (ATR)
- RDHL 0.09
- MBIO 0.15
- MACD
- RDHL 0.03
- MBIO -0.00
- Stochastic Oscillator
- RDHL 65.48
- MBIO 51.06
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.
About MBIO Mustang Bio Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.